Magdalena L Bochenek1,2,3, Christiane Leidinger1, Nico S Rosinus1,3, Rajinikanth Gogiraju1,3, Stefan Guth4, Lukas Hobohm1,2, Kerstin Jurk2, Eckhard Mayer4,3, Thomas Münzel1,3, Mareike Lankeit2,5, Markus Bosmann2,6, Stavros Konstantinides2,7, Katrin Schäfer1,3. 1. From the Center for Cardiology, Cardiology I (M.L.B., C.L., N.S.R., R.G., L.H., T.M., K.S.), University Medical Center Mainz, Germany. 2. Center for Thrombosis and Hemostasis (M.L.B., L.H., K.J., M.L., M.B., S.K.), University Medical Center Mainz, Germany. 3. German Center for Cardiovascular Research (DZHK e.V.; RheinMain) (M.L.B., N.S.R., R.G., E.M., T.M., K.S.). 4. Thoracic Surgery, Kerckhoff Clinic, Bad Nauheim, Germany (S.G., E.M.). 5. Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité -University Medicine, Berlin, Germany (M.L.). 6. Department of Medicine, Boston University School of Medicine, MA (M.B.). 7. Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece (S.K.).
Abstract
RATIONALE: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by defective thrombus resolution, pulmonary artery obstruction, and vasculopathy. TGFβ (transforming growth factor-β) signaling mutations have been implicated in pulmonary arterial hypertension, whereas the role of TGFβ in the pathophysiology of CTEPH is unknown. OBJECTIVE: To determine whether defective TGFβ signaling in endothelial cells contributes to thrombus nonresolution and fibrosis. METHODS AND RESULTS: Venous thrombosis was induced by inferior vena cava ligation in mice with genetic deletion of TGFβ1 in platelets (Plt.TGFβ-KO) or TGFβ type II receptors in endothelial cells (End.TGFβRII-KO). Pulmonary endarterectomy specimens from CTEPH patients were analyzed using immunohistochemistry. Primary human and mouse endothelial cells were studied using confocal microscopy, quantitative polymerase chain reaction, and Western blot. Absence of TGFβ1 in platelets did not alter platelet number or function but was associated with faster venous thrombus resolution, whereas endothelial TGFβRII deletion resulted in larger, more fibrotic and higher vascularized venous thrombi. Increased circulating active TGFβ1 levels, endothelial TGFβRI/ALK1 (activin receptor-like kinase), and TGFβRI/ALK5 expression were detected in End.TGFβRII-KO mice, and activated TGFβ signaling was present in vessel-rich areas of CTEPH specimens. CTEPH-endothelial cells and murine endothelial cells lacking TGFβRII simultaneously expressed endothelial and mesenchymal markers and transcription factors regulating endothelial-to-mesenchymal transition, similar to TGFβ1-stimulated endothelial cells. Mechanistically, increased endothelin-1 levels were detected in TGFβRII-KO endothelial cells, murine venous thrombi, or endarterectomy specimens and plasma of CTEPH patients, and endothelin-1 overexpression was prevented by inhibition of ALK5, and to a lesser extent of ALK1. ALK5 inhibition and endothelin receptor antagonization inhibited mesenchymal lineage conversion in TGFβ1-exposed human and murine endothelial cells and improved venous thrombus resolution and pulmonary vaso-occlusions in End.TGFβRII-KO mice. CONCLUSIONS: Endothelial TGFβ1 signaling via type I receptors and endothelin-1 contribute to mesenchymal lineage transition and thrombofibrosis, which were prevented by blocking endothelin receptors. Our findings may have relevant implications for the prevention and management of CTEPH.
RATIONALE: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by defective thrombus resolution, pulmonary artery obstruction, and vasculopathy. TGFβ (transforming growth factor-β) signaling mutations have been implicated in pulmonary arterial hypertension, whereas the role of TGFβ in the pathophysiology of CTEPH is unknown. OBJECTIVE: To determine whether defective TGFβ signaling in endothelial cells contributes to thrombus nonresolution and fibrosis. METHODS AND RESULTS:Venous thrombosis was induced by inferior vena cava ligation in mice with genetic deletion of TGFβ1 in platelets (Plt.TGFβ-KO) or TGFβ type II receptors in endothelial cells (End.TGFβRII-KO). Pulmonary endarterectomy specimens from CTEPHpatients were analyzed using immunohistochemistry. Primary human and mouse endothelial cells were studied using confocal microscopy, quantitative polymerase chain reaction, and Western blot. Absence of TGFβ1 in platelets did not alter platelet number or function but was associated with faster venous thrombus resolution, whereas endothelial TGFβRII deletion resulted in larger, more fibrotic and higher vascularized venous thrombi. Increased circulating active TGFβ1 levels, endothelial TGFβRI/ALK1 (activin receptor-like kinase), and TGFβRI/ALK5 expression were detected in End.TGFβRII-KO mice, and activated TGFβ signaling was present in vessel-rich areas of CTEPH specimens. CTEPH-endothelial cells and murine endothelial cells lacking TGFβRII simultaneously expressed endothelial and mesenchymal markers and transcription factors regulating endothelial-to-mesenchymal transition, similar to TGFβ1-stimulated endothelial cells. Mechanistically, increased endothelin-1 levels were detected in TGFβRII-KO endothelial cells, murinevenous thrombi, or endarterectomy specimens and plasma of CTEPHpatients, and endothelin-1 overexpression was prevented by inhibition of ALK5, and to a lesser extent of ALK1. ALK5 inhibition and endothelin receptor antagonization inhibited mesenchymal lineage conversion in TGFβ1-exposed human and murine endothelial cells and improved venous thrombus resolution and pulmonary vaso-occlusions in End.TGFβRII-KO mice. CONCLUSIONS: Endothelial TGFβ1 signaling via type I receptors and endothelin-1 contribute to mesenchymal lineage transition and thrombofibrosis, which were prevented by blocking endothelin receptors. Our findings may have relevant implications for the prevention and management of CTEPH.
Authors: Magdalena L Bochenek; Nico S Rosinus; Mareike Lankeit; Lukas Hobohm; Felix Bremmer; Eva Schütz; Frederikus A Klok; Sven Horke; Christoph B Wiedenroth; Thomas Münzel; Irene M Lang; Eckhard Mayer; Stavros Konstantinides; Katrin Schäfer Journal: Thromb Haemost Date: 2017-02-02 Impact factor: 5.249
Authors: Lai-Ming Yung; Ivana Nikolic; Samuel D Paskin-Flerlage; R Scott Pearsall; Ravindra Kumar; Paul B Yu Journal: Am J Respir Crit Care Med Date: 2016-11-01 Impact factor: 21.405
Authors: Marie-Luise von Brühl; Konstantin Stark; Alexander Steinhart; Sue Chandraratne; Ildiko Konrad; Michael Lorenz; Alexander Khandoga; Anca Tirniceriu; Raffaele Coletti; Maria Köllnberger; Robert A Byrne; Iina Laitinen; Axel Walch; Alexander Brill; Susanne Pfeiler; Davit Manukyan; Siegmund Braun; Philipp Lange; Julia Riegger; Jerry Ware; Annekathrin Eckart; Selgai Haidari; Martina Rudelius; Christian Schulz; Katrin Echtler; Volker Brinkmann; Markus Schwaiger; Klaus T Preissner; Denisa D Wagner; Nigel Mackman; Bernd Engelmann; Steffen Massberg Journal: J Exp Med Date: 2012-03-26 Impact factor: 14.307
Authors: Christopher Lambers; Michael Roth; Jun Zhong; Christoph Campregher; Petra Binder; Bernhard Burian; Ventzislav Petkov; Lutz-Henning Block Journal: PLoS One Date: 2013-08-28 Impact factor: 3.240
Authors: Colin E Evans; Steven P Grover; Julia Humphries; Prakash Saha; Anant P Patel; Ashish S Patel; Oliver T Lyons; Matt Waltham; Bijan Modarai; Alberto Smith Journal: Arterioscler Thromb Vasc Biol Date: 2014-01-16 Impact factor: 8.311
Authors: George A Alba; Deepak Atri; Sriranjani Darbha; Inderjit Singh; Victor F Tapson; Michael I Lewis; Hyung J Chun; Yen-Rei Yu; Bradley A Maron; Sudarshan Rajagopal Journal: Curr Cardiol Rep Date: 2021-08-19 Impact factor: 2.931
Authors: Marion Pilard; Estelle L Ollivier; Virginie Gourdou-Latyszenok; Francis Couturaud; Catherine A Lemarié Journal: Front Cardiovasc Med Date: 2022-04-21